NASDAQ:GLYC GlycoMimetics (GLYC) Stock Price, News & Analysis $0.24 +0.01 (+4.33%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.23▼$0.2550-Day Range$0.24▼$0.3352-Week Range$0.20▼$3.53Volume1.45 million shsAverage Volume2.25 million shsMarket Capitalization$15.55 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get GlycoMimetics alerts: Email Address GlycoMimetics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside4,045.9% Upside$10.00 Price TargetShort InterestHealthy4.42% of Shares Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment0.05Based on 8 Articles This WeekInsider TradingAcquiring Shares$47,500 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.62) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.62 out of 5 starsMedical Sector75th out of 936 stocksPharmaceutical Preparations Industry26th out of 436 stocks 3.0 Analyst's Opinion Consensus RatingGlycoMimetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageGlycoMimetics has only been the subject of 3 research reports in the past 90 days.Read more about GlycoMimetics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.42% of the outstanding shares of GlycoMimetics have been sold short.Short Interest Ratio / Days to CoverGlycoMimetics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlycoMimetics has recently decreased by 44.23%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlycoMimetics does not currently pay a dividend.Dividend GrowthGlycoMimetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlycoMimetics has received a 73.56% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for GlycoMimetics is -0.55. Previous Next 1.7 News and Social Media Coverage News SentimentGlycoMimetics has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for GlycoMimetics this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for GLYC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GlycoMimetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $47,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.70% of the stock of GlycoMimetics is held by insiders.Percentage Held by Institutions75.19% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GlycoMimetics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for GlycoMimetics are expected to grow in the coming year, from ($0.62) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GlycoMimetics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlycoMimetics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlycoMimetics has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about GlycoMimetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About GlycoMimetics Stock (NASDAQ:GLYC)GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Read More GLYC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLYC Stock News HeadlinesJuly 26 at 6:28 PM | markets.businessinsider.comGlycoMimetics: Strategic Overhaul and FDA Setback Justify Hold RatingJuly 25 at 9:43 PM | msn.comGlycoMimetics to cut workforce by about 80% in corporate restructuring planJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 25 at 9:43 PM | marketwatch.comGlycoMimetics Shares Drop 27% After Restructuring Plan, Job CutsJuly 25 at 9:43 PM | finance.yahoo.comGlycoMimetics Announces Strategic Review and Corporate Restructuring PlanJuly 25 at 1:24 AM | americanbankingnews.comStockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC)July 18, 2024 | americanbankingnews.comGlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.comJune 4, 2024 | businesswire.comGlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)July 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 29, 2024 | businesswire.comGlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024May 28, 2024 | finance.yahoo.comPipeline Moves: Phase III AML trial fails to meet primary endpointMay 10, 2024 | msn.comGlycoMimetics GAAP EPS of -$0.17 in-lineMay 9, 2024 | msn.comGlycoMimetics Q1 2024 Earnings PreviewMay 8, 2024 | markets.businessinsider.comSell Rating on Lyra Therapeutics Amid Phase 3 Study Failure and Funding ConcernsMay 7, 2024 | msn.comHC Wainwright & Co. Downgrades GlycoMimetics (GLYC)May 6, 2024 | msn.comGlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares SinkMay 6, 2024 | markets.businessinsider.comWhy Is GlycoMimetics Stock Falling In Pre-market?May 6, 2024 | marketwatch.comGlycoMimetics Shares Drop After Leukemia Treatment Trial Fails to Meet Primary EndpointSee More Headlines Receive GLYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLYC CUSIPN/A CIK1253689 Webwww.glycomimetics.com Phone(240) 243-1201Fax301-738-2137Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$12.00 Low Stock Price Target$8.00 Potential Upside/Downside+4,045.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,900,000.00 Net MarginsN/A Pretax Margin-372,770.03% Return on Equity-88.40% Return on Assets-76.65% Debt Debt-to-Equity RatioN/A Current Ratio6.28 Quick Ratio6.28 Sales & Book Value Annual Sales$10,000.00 Price / Sales1,554.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book0.40Miscellaneous Outstanding Shares64,460,000Free Float58,856,000Market Cap$15.55 million OptionableOptionable Beta2.19 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Harout Semerjian (Age 54)CEO, President & Director Comp: $1.13MMs. Rachel K. King (Age 65)Co-Founder & Director Comp: $40kMr. Brian M. Hahn (Age 50)Senior VP & CFO Comp: $822.12kDr. Edwin Rock M.D. (Age 63)Ph.D., Senior VP & Chief Medical Officer Comp: $677.4kMs. Stephanie R. Irish CPA (Age 53)Vice President of Accounting Mr. Christian B. Dinneen-LongGeneral Counsel & Company SecretaryMr. Bruce Johnson (Age 56)Senior VP & Chief Commercial Officer Mr. Chinmaya Rath (Age 47)Senior VP & Chief Business Officer Mr. Shantha Tyavanagimatt Ph.D.Senior Vice President of Technical OperationsMore ExecutivesKey CompetitorsOvid TherapeuticsNASDAQ:OVIDTheratechnologiesNASDAQ:THTXConnect BiopharmaNASDAQ:CNTBEupraxia PharmaceuticalsNASDAQ:EPRXAlaunos TherapeuticsNASDAQ:TCRTView All CompetitorsInsiders & InstitutionsEdwin RockBought 190,000 shares on 6/20/2024Total: $47,500.00 ($0.25/share)Ikarian Capital LLCBought 172,800 shares on 5/17/2024Ownership: 0.000%NEA Management Company LLCSold 929,401 shares on 5/15/2024Ownership: 5.949%Affinity Asset Advisors LLCBought 142,300 shares on 5/15/2024Ownership: 0.000%Vanguard Group Inc.Bought 340,112 shares on 5/10/2024Ownership: 4.285%View All Insider TransactionsView All Institutional Transactions GLYC Stock Analysis - Frequently Asked Questions How have GLYC shares performed this year? GlycoMimetics' stock was trading at $2.36 at the beginning of the year. Since then, GLYC shares have decreased by 89.8% and is now trading at $0.2412. View the best growth stocks for 2024 here. How were GlycoMimetics' earnings last quarter? GlycoMimetics, Inc. (NASDAQ:GLYC) announced its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. How do I buy shares of GlycoMimetics? Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of GlycoMimetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX) and Spectrum Pharmaceuticals (SPPI). This page (NASDAQ:GLYC) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.